Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHLGet Rating) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 150,800 shares, a growth of 20.1% from the March 31st total of 125,600 shares. Based on an average daily trading volume, of 102,500 shares, the short-interest ratio is presently 1.5 days. Approximately 0.4% of the shares of the stock are sold short.

Large investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC lifted its holdings in Achilles Therapeutics by 25.0% in the 3rd quarter. Affinity Asset Advisors LLC now owns 100,000 shares of the company’s stock valued at $779,000 after purchasing an additional 20,000 shares in the last quarter. BlackRock Inc. purchased a new position in Achilles Therapeutics in the 4th quarter valued at about $1,064,000. Citadel Advisors LLC purchased a new position in Achilles Therapeutics in the 4th quarter valued at about $283,000. Geode Capital Management LLC purchased a new position in Achilles Therapeutics in the 3rd quarter valued at about $137,000. Finally, Renaissance Technologies LLC purchased a new position in Achilles Therapeutics in the 4th quarter valued at about $128,000. Institutional investors own 67.57% of the company’s stock.

Achilles Therapeutics stock opened at $2.21 on Tuesday. Achilles Therapeutics has a 52 week low of $2.03 and a 52 week high of $16.53. The company has a quick ratio of 14.90, a current ratio of 14.90 and a debt-to-equity ratio of 0.03. The stock has a 50-day simple moving average of $2.86. The stock has a market cap of $89.73 million and a price-to-earnings ratio of -0.23.

Achilles Therapeutics (NASDAQ:ACHLGet Rating) last released its quarterly earnings data on Tuesday, March 1st. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). As a group, research analysts forecast that Achilles Therapeutics will post -2.03 earnings per share for the current fiscal year.

Separately, Piper Sandler decreased their price objective on shares of Achilles Therapeutics from $23.00 to $20.00 in a research report on Tuesday, March 1st.

Achilles Therapeutics Company Profile (Get Rating)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

Recommended Stories

Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.